• Molecular NamePseudoephedrine
  • SynonymNA
  • Weight165.236
  • Drugbank_IDDB00852
  • ACS_NO90-82-4
  • Show 3D model
  • LogP (experiment)0.9
  • LogP (predicted, AB/LogP v2.0)1.05
  • pka9.8
  • LogD (pH=7, predicted)-1.27
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)0.78
  • LogSw (predicted, AB/LogsW2.0)80.66
  • Sw (mg/ml) (predicted, ACD/Labs)38.66
  • No.of HBond Donors2
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds3
  • TPSA32.26
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA sympathomimetic drug of the phenethylamine and amphetamine chemical classes used as a nasal/sinus decongestant and stimulant or wakefulness-promoting agent.
  • Absorption_value100.0
  • Absorption (description)Pseudoephedrine is readily and almost completely absorbed from the GI tract and there is no evidence of first-pass metabolism.
  • Caco_2N/A
  • Bioavailability100.0
  • Protein bindingN/A
  • Volume of distribution (VD)3 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmPseudoephedrine is extensively reabsorbed
  • Half life4.3~8 h
  • Excretion70-90% renal
  • Urinary Excretion43~96
  • Clerance7.33 ml/min/kg
  • ToxicityCommon adverse reactions include nervousness, restlessness, and insomnia. Rare adverse reactions include difficult/painful urination, dizziness/lightheadedness, heart palpitations, headache, increased sweating, nausea/vomiting, trembling, troubled breathing, unusual paleness, and weakness.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A